A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Topiramate Controlled Release in the Treatment of Obese Type 2 Diabetic Patients
Open accessAbstract
OBJECTIVE—This is a randomized, placebo-controlled study of the weight-loss efficacy and safety of a controlled-release (CR) formulation of topiramate in overweight and obese patients with type 2 diabetes treated with diet and exercise alone or in combination with metformin. RESEARCH DESIGN AND METHODS—Patients with type 2 diabetes, BMI ≥27 kg/m2, A1C >6.5 and <11.0%, treated with diet and exercise alone or in combination with metformin monotherapy were enrolled. Patients were randomized to placebo or topiramate CR titrated up to 175 mg/day. Treatment consisted of a 7-week titration phase followed by a 9-week maintenance phase. RESULTS—A total of 111 subjects were randomized and analyzed. By the end of week 16, patients in the placebo and topiramate groups lost 2.5 and 6.0 kg, which represented 2.3 and 5.8%, respectively, of their baseline body weight (P < 0.001 vs. placebo). A1C improved from a baseline of 7.4% in the placebo and 7.6% in the topiramate groups to 7.1 and 6.7%, respectively, representing a 0.4 and 0.9% reduction from baseline, respectively (P < 0.001 vs. placebo). Topiramate also significantly reduced blood pressure and urinary albumin excretion. Adverse events were predominantly neuropsychiatric or central and peripheral nervous system related. CONCLUSIONS—Topiramate CR treatment produced significant weight loss and meaningful improvements in A1C and blood pressure in obese patients with type 2 diabetes treated with diet and exercise or in combination with metformin. However, the central nervous system and psychiatric adverse event profile of topiramate CR makes it unsuitable for the treatment of obesity and diabetes.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Robins, L. N. (1981) · Archives of General Psychiatry · doi:10.1001/archpsyc.1981.01780290015001 · Cited by 5,219 · see citing works
Use and Abuse of HOMA Modeling
Wallace, T. M., Levy, J. C., & Matthews, D. R. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1487 · Cited by 5,114 · see citing works
Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery
Sjöström, L., Lindroos, A.-K., Peltonen, M., Torgerson, J., Bouchard, C., Carlsson, B., Dahlgren, S., Larsson, B., Narbro, K., Sjöström, C. D., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035622 · Cited by 4,457 · see citing works
Diet, lifestyle, and the risk of type 2 diabetes mellitus in women.
Hu, F. B., Manson, J. E., Stampfer, M. J., Colditz, G., Liu, S., Solomon, C. G., & Willett, W. C. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010492 · Cited by 2,901 · see citing works
Arky, R. A. (1994) · Cited by 2,632 · see citing works
Obesity, Fat Distribution, and Weight Gain as Risk Factors for Clinical Diabetes in Men
Chan, J. M., Rimm, E. B., Colditz, G. A., Stampfer, M. J., & Willett, W. C. (1994) · Diabetes Care · doi:10.2337/diacare.17.9.961 · Cited by 1,808 · see citing works
Gibbs, J. W., Sombati, S., DeLorenzo, R. J., & Coulter, D. A. (2000) · Epilepsia · doi:10.1111/j.1528-1157.2000.tb02164.x · Cited by 349 · see citing works
Bray, G. A., Hollander, P., Klein, S., Kushner, R., Levy, B., Fitchet, M., & Perry, B. H. (2003) · Obesity Research · doi:10.1038/oby.2003.102 · Cited by 344 · see citing works
Self-citationfor the OBES-002 Study Group, Wilding, J., Gaal, L. V., Rissanen, A., Vercruysse, F., & Fitchet, M. (2004) · International Journal of Obesity · doi:10.1038/sj.ijo.0802783 · Cited by 224 · see citing works
Self-citationInfluence of topiramate in the regulation of energy balance
Richard, D., Ferland, J., Lalonde, J., Samson, P., & Deshaies, Y. (2000) · Nutrition · doi:10.1016/s0899-9007(00)00452-4 · Cited by 161 · see citing works
Topiramate: Long‐Term Maintenance of Weight Loss Induced by a Low‐Calorie Diet in Obese Subjects
Astrup, A., Caterson, I., Zelissen, P., Guy‐Grand, B., Carruba, M., Levy, B., Sun, X., Fitchet, M., & OBES‐004 Study Group (2004) · Obesity Research · doi:10.1038/oby.2004.206 · Cited by 143 · see citing works
Self-citationEffect of Sibutramine on Weight Management and Metabolic Control in Type 2 Diabetes
Vettor, R., Serra, R., Fabris, R., Pagano, C., & Federspil, G. (2005) · Diabetes Care · doi:10.2337/diacare.28.4.942 · Cited by 105 · see citing works
Husum, H., van Kammen, D., Termeer, E. H., Bolwig, T. G., & Mathé, A. A. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300178 · Cited by 96 · see citing works
Topiramate in the treatment of obese subjects with drug‐naive type 2 diabetes
Stenlöf, K., Rössner, S. M., Vercruysse, F., Kumar, A., Fitchet, M., Sjöström, L., & Study Group (2006) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00618.x · Cited by 78 · see citing works
for the OBDM-002 Study Group, Toplak, H., Hamann, A., Moore, R., Masson, E., Górska, M., Vercruysse, F., Sun, X., & Fitchet, M. (2006) · International Journal of Obesity · doi:10.1038/sj.ijo.0803382 · Cited by 74 · see citing works
Self-citationEfficacy and Safety of Topiramate in the Treatment of Obese Subjects With Essential Hypertension
Tonstad, S., Tykarski, A., Weissgarten, J., Ivleva, A. Y., Levy, B., Kumar, A., & Fitchet, M. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.03.053 · Cited by 72 · see citing works
Curran, M. P., & Scott, L. J. (2004) · Drugs · doi:10.2165/00003495-200464240-00010 · Cited by 52 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- [12]12. Wong PSL, Gupta SK, Stewart BD: Os- motically controlled tablets. In Drugs and the Pharmaceutical Sciences: Modified- Release Drug Delivery Technology. Vol. 126. Rathbone MJ et al., Eds. New York, Marcel Dekker, 2003
Cited by
Sorted by citations
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914 · see citing works
Gadde, K. M., Allison, D. B., Ryan, D. H., Peterson, C. A., Troupin, B., Schwiers, M. L., & Day, W. W. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60205-5 · Cited by 1,064 · see citing works
Self-citationGarvey, W. T., Ryan, D. H., Look, M., Gadde, K. M., Allison, D. B., Peterson, C. A., Schwiers, M., Day, W. W., & Bowden, C. H. (2012) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.024927 · Cited by 716 · see citing works
Self-citationAronne, L. J., Wadden, T. A., Peterson, C., Winslow, D., Odeh, S., & Gadde, K. M. (2013) · Obesity · doi:10.1002/oby.20584 · Cited by 274 · see citing works
Self-citationWeight Management in Type 2 Diabetes: Current and Emerging Approaches to Treatment
Van Gaal, L., & Scheen, A. (2015) · Diabetes Care · doi:10.2337/dc14-1630 · Cited by 221 · see citing works
Winslow, D. H., Bowden, C. H., DiDonato, K. P., & McCullough, P. A. (2012) · Sleep · doi:10.5665/sleep.2204 · Cited by 163 · see citing works
Gummesson, A., Nyman, E., Knutsson, M., & Karpefors, M. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12971 · Cited by 162 · see citing works
Effectiveness and safety of drugs for obesity
Henderson Lewis, K., Sloan, C. E., Bessesen, D. H., & Arterburn, D. (2024) · BMJ · doi:10.1136/bmj-2022-072686 · Cited by 66 · see citing works
Combination phentermine and topiramate extended release in the management of obesity.
Alfaris, N., Minnick, A. M., Hopkins, C. M., Berkowitz, R. I., & Wadden, T. A. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1041505 · Cited by 38 · see citing works
- Authors
- Rosenstock, J., Hollander, P., Gadde, K. M., Sun, X., Strauss, R., Leung, A., & for the OBD-202 Study Group
- Affiliations
- Dallas Diabetes and Endocrine Center, Dallas, Texas
- Baylor University Medical Center (US)
- Duke University (US)
- Janssen Research & Development (United States) (US)
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2007-06-01
- Volume
- 30
- Issue
- 6
- Pages
- 1480-1486
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2008985927
- Cited by
- 85
- References
- 17
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 5 · 2021: 3 · 2020: 2 · 2019: 2 · 2018: 2 · 2017: 2 · 2016: 3 · 2015: 5 · 2014: 9 · 2013: 7 · 2012: 8
- FWCI
- 5.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- topiramate, controlled-release formulation, type 2 diabetes, obesity, weight loss, glycemic control, HbA1c, metformin, blood pressure, urinary albumin excretion, neuropsychiatric adverse effects
- MeSH terms
- Topiramate, Adult, Aged, Delayed-Action Preparations, Diabetes Mellitus, Type 2, Diet, Reducing, Double-Blind Method, Female, Fructose, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Obesity, Placebos, Safety, Exercise, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
